YY524051

Primary Objective: To evaluate the safety and tolerability of single and multiple oral doses of YY524051 tablets in healthy participants. Secondary Objectives: ① To evaluate the pharmacokinetic (PK) characteristics of single and multiple oral doses of YY524051 tablets in healthy participants; ② To evaluate the PK characteristics of a single oral dose of YY524051 tablets under high-fat meal conditions in healthy participants; ③ To evaluate the effect of a single oral dose of YY524051 tablets on the QT/QTc interval in healthy participants. Exploratory Objective: To evaluate exploratory endpoints of YY524051 tablets after multiple administrations in healthy participants.